Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues FY 2026 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.200-1.346 for the period, compared to the consensus EPS estimate of 1.200. The company issued revenue guidance of $52.1 billion-$54.5 billion, compared to the consensus revenue estimate of $53.2 billion.

Analyst Ratings Changes

Several brokerages recently weighed in on BAYRY. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. Finally, DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Thursday, April 9th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy”.

Bayer Aktiengesellschaft Trading Up 3.0%

Shares of OTCMKTS BAYRY opened at $11.21 on Wednesday. Bayer Aktiengesellschaft has a fifty-two week low of $6.20 and a fifty-two week high of $14.85. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.01 and a quick ratio of 0.63. The firm has a market capitalization of $44.06 billion, a P/E ratio of -10.10 and a beta of 0.62. The company’s 50 day simple moving average is $11.29 and its 200 day simple moving average is $10.93.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Wednesday, March 4th. The company reported $0.18 EPS for the quarter, meeting the consensus estimate of $0.18. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.93%. The firm had revenue of $13.24 billion during the quarter, compared to the consensus estimate of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. On average, analysts predict that Bayer Aktiengesellschaft will post 1.2 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.